Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
Pharmacotherapeutic Management and Enhanced Elimination Strategies

Pharmacotherapeutic Management and Enhanced Elimination Strategies

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objectives

After completing this chapter, the reader will be able to apply principles of toxin neutralization with specific antidotes and utilize enhanced elimination techniques, including decontamination and extracorporeal removal, to manage acute poisonings.

1. Principles of Pharmacotherapy in Acute Overdoses

Early toxin neutralization and enhanced elimination are foundational to managing acute overdoses. Rapid intervention within defined toxicity windows is critical to reduce the risk of irreversible organ injury. The decision to escalate from supportive care to more invasive measures like extracorporeal removal is guided by a comprehensive risk stratification that includes patient history, serum toxin levels, and clinical symptoms.

Overdose Management Flowchart A flowchart showing the decision-making process for managing an acute overdose, starting with initial assessment, moving to decontamination and antidotal therapy, and escalating to enhanced elimination if necessary. Patient with Acute Overdose Adsorbable Toxin & <1 hr? No Yes Administer Activated Charcoal Specific Antidote Available? No Yes Administer Antidote (e.g., NAC, Bicarbonate) Supportive Care & Escalate if Worsening
Figure 1: Overdose Management Pathway. Initial management focuses on decontamination and specific antidotes. Escalation to enhanced elimination is considered for patients with severe toxicity or those who fail initial therapies.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: The “Toxicity Window”

The “toxicity window” denotes the critical period during which antidotal therapy can prevent or mitigate permanent organ injury. For example, initiating N-acetylcysteine (NAC) within 8 hours of a significant acetaminophen ingestion dramatically reduces the risk of severe hepatotoxicity.

2. Antidotal Therapy

A. N-acetylcysteine (NAC) for Acetaminophen Overdose

NAC is a life-saving antidote that prevents hepatic necrosis by replenishing intracellular glutathione stores, which are essential for detoxifying the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). It also has direct antioxidant and anti-inflammatory properties.

  • Indications: Serum acetaminophen level above the treatment line on the Rumack–Matthew nomogram (e.g., >150 µg/mL at 4 hours post-ingestion); unknown ingestion time with evidence of liver injury; or high-risk patients (chronic ethanol use, malnutrition, pregnancy).
  • Formulations: Intravenous (IV) is preferred in patients with vomiting, hepatic encephalopathy, or unreliable GI absorption. Oral is an alternative in stable patients but carries a risk of emesis and delayed delivery.
  • Dosing Regimens:
    • IV (3-bag protocol): 150 mg/kg over 1 hour, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (total 300 mg/kg).
    • Oral: 140 mg/kg loading dose, followed by 70 mg/kg every 4 hours for 17 doses.
  • Monitoring: Acetaminophen levels at 4 hours post-ingestion and per institutional protocol. Monitor liver function tests (LFTs), INR, and renal function every 12–24 hours. Watch for anaphylactoid reactions (approximately 15% with IV NAC), which can be managed by slowing the infusion and administering antihistamines.
Controversy IconA chat bubble with a question mark, indicating a point of controversy or debate. Guideline Controversy: Simplified IV Regimens

Simplified 2-bag IV regimens (e.g., 200 mg/kg over 4 hours, then 100 mg/kg over 16 hours) have been proposed to reduce medication errors and complexity. While promising, they require more robust clinical outcome data before widespread adoption over the traditional 3-bag protocol.

B. Sodium Bicarbonate for Salicylate Toxicity

Alkalinization with sodium bicarbonate is a key intervention that shifts salicylate from its lipid-soluble, non-ionized form to its water-soluble, ionized form. This “ion trapping” enhances renal clearance and, crucially, reduces its penetration into the central nervous system.

  • Indications: Serum salicylate >30 mg/dL with symptoms (tinnitus, tachypnea) or >50 mg/dL regardless of symptoms; presence of metabolic acidosis.
  • Dosing: An initial bolus of 1–2 mEq/kg IV, followed by a continuous infusion (e.g., 150 mEq in 1 L D5W) titrated to maintain a serum pH of 7.45–7.50 and a urine pH >7.5.
  • Monitoring: Arterial blood gases (ABGs) every 1–2 hours initially, along with electrolytes (especially potassium) and volume status. Hypokalemia must be corrected, as it impairs the kidney’s ability to alkalinize urine.
  • Role vs. Hemodialysis: Hemodialysis is the definitive treatment and should be initiated for severe toxicity (salicylate >100 mg/dL), acute kidney injury, refractory acidosis, or CNS deterioration (seizures, coma).

3. Gastrointestinal Decontamination

Activated charcoal (AC) can significantly reduce systemic absorption of certain toxins by adsorbing them within the GI tract. Its effectiveness is highly time-dependent.

  • Indications: Ingestion of a charcoal-adsorbable toxin (most organic compounds) within 1 hour. Multi-dose activated charcoal (MDAC) may be beneficial for toxins with enterohepatic recirculation (e.g., theophylline, phenobarbital) or in extended-release formulations.
  • Dosing: A single dose is 50–100 g for adults (0.5–1 g/kg for children). MDAC is typically dosed as 12.5 g/hour or 0.5 g/kg every 4 hours.
  • Contraindications: Unprotected airway (risk of aspiration), ingestion of caustics or hydrocarbons, and known bowel obstruction.
  • Pitfalls: Aspiration pneumonitis is a serious risk if the airway is not protected. Nasogastric tubes can become occluded if the charcoal slurry is not properly diluted and flushed.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: MDAC for Theophylline

Multi-dose activated charcoal (MDAC) can increase the clearance of theophylline by up to fourfold. This makes it a critical intervention, especially in settings where hemodialysis is not immediately available.

4. Enhanced Elimination Techniques

Extracorporeal methods like hemodialysis (HD) and hemoperfusion are used to rapidly remove certain toxins from the bloodstream and correct severe metabolic disturbances. Selection is based on toxin properties such as volume of distribution (Vd) and protein binding.

Indications for Enhanced Elimination
Toxin Treatment Threshold Preferred Modality Key Characteristics
Lithium >4 mmol/L (acute) or severe symptoms Intermittent HD Low Vd, low protein binding
Salicylates >100 mg/dL or severe end-organ damage Intermittent HD Low Vd, concentration-dependent binding
Theophylline >100 µg/mL or life-threatening symptoms Intermittent HD Low Vd, moderately protein bound
Paraquat Any severe ingestion Charcoal Hemoperfusion High affinity for charcoal adsorbent
  • Modality Selection: HD is effective for small, water-soluble toxins with low protein binding (e.g., lithium, salicylates). Hemoperfusion, which passes blood over an adsorbent cartridge, is used for toxins with high affinity for the adsorbent (e.g., paraquat).
  • Prescription: Requires a double-lumen dialysis catheter. Typical blood flow rates are 200–300 mL/min with a dialysate flow of 500 mL/min for a session of at least 4 hours.
  • Monitoring: Pre- and post-treatment toxin levels are essential to confirm clearance. Monitor for rebound toxicity as the toxin redistributes from tissues back into the plasma; repeat sessions may be necessary.

5. Supportive Pharmacotherapy for Agent-Specific Toxicities

A. Theophylline Overdose

Theophylline toxicity causes a catecholamine surge and adenosine receptor antagonism, leading to refractory seizures and tachyarrhythmias.

  • Management: Administer single-dose charcoal, followed by MDAC. Proceed to hemodialysis if the level is >100 µg/mL or if severe symptoms are present.
  • Arrhythmias: Titrate an esmolol infusion (50–300 µg/kg/min) to a heart rate <100/min.
  • Seizures: Use benzodiazepines as first-line therapy. Phenytoin is ineffective and should be avoided.
  • Metabolic: Aggressively correct hypokalemia, hypomagnesemia, and hypophosphatemia.

B. Paraquat/Diquat Poisoning

There is no specific antidote for these highly lethal herbicides. Management focuses on immediate decontamination, early extracorporeal removal, and mitigating oxidative lung injury.

  • Supportive Measures: Initiate charcoal hemoperfusion as early as possible. Use conservative oxygen therapy (target SpO₂ 88-92%) to avoid amplifying free radical production in the lungs. Aggressive fluid resuscitation is crucial.
  • Monitoring: Closely monitor pulmonary status with imaging and oxygenation indices, as well as daily renal and hepatic function panels.

6. Special Populations and Dose Adjustments

Antidote and decontamination strategies must be tailored for patients with comorbid conditions, at the extremes of age, or with potential drug interactions.

  • Renal Impairment: Use lower thresholds for initiating hemodialysis. In acetaminophen overdose with concurrent chronic kidney disease, the NAC infusion may need to be prolonged.
  • Elderly: Reduced metabolic clearance may necessitate slower initiation and careful titration of antidotes like NAC, guided by serial LFT and INR trends.
  • Pediatrics: Dosing is weight-based. For NAC, the IV loading dose is 150 mg/kg and the oral dose is 70 mg/kg every 4 hours. MDAC is typically 0.5 g/kg every 4 hours.

7. Monitoring and Follow-Up

Serial assessment of toxin levels and organ function is essential to guide the duration of therapy, detect rebound toxicity, and plan for a safe discharge.

  • Serial Toxin Concentrations:
    • Acetaminophen: At 4, 16, and 24 hours post-ingestion, and until cleared.
    • Salicylates: Every 2–4 hours until levels are consistently decreasing and acidosis resolves.
    • Theophylline: Every 2 hours initially during acute management.
  • Organ Function Tests: Monitor LFTs, INR, and creatinine every 12–24 hours. Obtain frequent ABGs during alkalinization therapy.
  • Discharge Criteria: Toxin levels must be below treatment thresholds, with stable vital signs and organ function. Ensure patient education on medication safety and arrange for necessary follow-up labs.

References

  1. Larson AM, et al. Intravenous N-acetylcysteine for acute liver failure from acetaminophen poisoning: A randomized clinical trial. JAMA Netw Open. 2023;6(8):e2327182.
  2. Ontario Poison Centre. Intravenous N-Acetylcysteine. Toronto, ON; 2019.
  3. American College of Medical Toxicology. ACMT Position Statement: Management Priorities in Salicylate Toxicity. J Med Toxicol. 2022.
  4. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol. 1999;37(6):731–751.
  5. Giardino R, et al. Hemoperfusion in paraquat poisoning. Artif Organs. 1995;19(4):362–365.
  6. Eddleston M, et al. The clinical pharmacology of paraquat in patients with moderately severe poisoning. Clin Toxicol. 2011;49(9):789–796.
  7. Spiller HA, et al. Theophylline poisoning: a case series of 301 patients. JAMA Intern Med. 1999;159(9):1043–1048.
  8. Decker BS, Goldfarb DS, Dargan PI, et al; EXTRIP Workgroup. Extracorporeal treatment for lithium poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin J Am Soc Nephrol. 2015;10(5):875-887.
  9. Juurlink DN, Gosselin S, Kielstein JT, et al; EXTRIP Workgroup. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP workgroup. Ann Emerg Med. 2015;66(2):165-181.
  10. American College of Medical Toxicology. ACMT Position Statement: Duration of Intravenous N-acetylcysteine Therapy Following Acetaminophen Overdose. J Med Toxicol. 2017;13(1):126–127.
  11. Roat B. Pharmacotherapeutic management of common toxicologic emergencies. Crit Care Pharm. 2023;15(2):45–52.